Incyte’s $1.25B Buyout Brings What Could Become the Next Big Bleeding Disorder Drug

Incyte’s Vega Therapeutics acquisition comes with a late-stage drug offering a novel mechanism of action and a dosing advantage compared to currently available therapies for von Willebrand disease, an inherited bleeding disorder. The deal comes as patent expiration looms for Jakafi, currently Incyte’s top product. The post Incyte’s $1.25B Buyout Brings What Could Become the…

Read More

How AI is Unlocking Smarter Clinical Trial Protocols

By fine-tuning domain-specific models with real clinical operations data — such as historical performance, feasibility outcomes, enrollment patterns, and resource utilization — hidden information can be translated into structured intelligence. The post How AI is Unlocking Smarter Clinical Trial Protocols appeared first on MedCity News.

Read More

An Update on Medicaid, Title X and Planned Parenthood

This brief provides an update on Planned Parenthood closures and participation in the Title X program in the midst of substantial policy changes leading to decreased funding for Planned Parenthood including the One Big Beautiful Bill Act and the withholding of federal Title X funding to Planned Parenthood clinics.

Read More